An Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC
Condition: Recurrent Basal Cell Carcinoma Interventions: Drug: Patidegib Topical Gel, 2%; Drug: Patidegib Topical Gel, Vehicle Sponsor: PellePharm, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials